Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of October 2020, with a specific reporting date of October 13, 2020. The document serves as a transaction notification regarding dealings in the company's ordinary shares by Persons Discharging Managerial Responsibilities (PDMRs).
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. It exclusively reports on specific share transactions:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Type: Acquisition of shares via dividend reinvestment within an Individual Savings Account (ISA).
- Transaction Date: October 9, 2020.
- Transaction Price: £14.3235 per share.
- Volumes:
- Mr. D Redfern (Chief Strategy Officer): 28 shares.
- Ms. V Whyte (Company Secretary): 24 shares.
- Exchange: London Stock Exchange (XLON).
Material Changes
The filing does not report material changes to the company's financial position, operations, or strategy compared to prior periods. It solely documents routine share acquisitions resulting from dividend reinvestment plans for two specific executives.
Guidance, Outlook, and Risks
The document contains no management commentary, forward-looking guidance, risk factors, contingencies, or discussion of unusual items. It is a statutory disclosure of insider trading activity.
Key Facts for Investor Verification
- Verify the dividend reinvestment plan terms applicable to GSK shares held in ISAs as of October 2020.
- Confirm the market price of GSK ordinary shares on October 9, 2020, to validate the reported transaction price of £14.3235.
- Note that the reported share volumes (28 and 24 shares) are nominal and do not indicate significant changes in executive ownership stakes.